Cargando…

The effect of mTOR inhibitors on respiratory infections in lymphangioleiomyomatosis

Lymphangioleiomyomatosis (LAM) is a destructive cystic lung disease. Mammalian target of rapamycin (mTOR) inhibitors are the primary treatment for LAM but it is unknown whether these immunosuppressing medications increase the risk for or the severity of respiratory infections in LAM patients. We sea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Courtwright, Andrew M., Goldberg, Hilary J., Henske, Elizabeth Petri, El-Chemaly, Souheil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Respiratory Society 2017
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9484491/ https://www.ncbi.nlm.nih.gov/pubmed/28096282 http://dx.doi.org/10.1183/16000617.0004-2016

Ejemplares similares

Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer
por: El-Chemaly, Souheil, et al.
Publicado: (2014)

Serum endostatin levels are associated with diffusion capacity and with tuberous sclerosis- associated lymphangioleiomyomatosis
por: Lamattina, Anthony M., et al.
Publicado: (2019)

Lymphangioleiomyomatosis: circulating levels of FGF23 and pulmonary diffusion
por: Esposito, Anthony J, et al.
Publicado: (2023)

Lost in translation: a neglected mTOR target for lymphangioleiomyomatosis
por: Evans, Jilly F., et al.
Publicado: (2023)

The efficacy and adverse events of mTOR inhibitors in lymphangioleiomyomatosis: systematic review and meta-analysis
por: Gao, Nannan, et al.
Publicado: (2018)

The lung microbiome in end-stage Lymphangioleiomyomatosis
por: Ng, Julie, et al.
Publicado: (2021)

mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012)

mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges
por: Zou, Zhilin, et al.
Publicado: (2020)

mTOR Signaling in Cancer and mTOR Inhibitors in Solid Tumor Targeting Therapy
por: Tian, Tian, et al.
Publicado: (2019)

Overcoming mTOR Resistance Mutations with a New Generation mTOR Inhibitor
por: Rodrik-Outmezguine, Vanessa S., et al.
Publicado: (2016)

Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
por: Hassan, Burhan, et al.
Publicado: (2014)

Midkine expression by stem-like tumor cells drives persistence to mTOR inhibition and an immune-suppressive microenvironment
por: Tang, Yan, et al.
Publicado: (2022)

mTORC1 hyperactivation in lymphangioleiomyomatosis leads to ACE2 upregulation in type II pneumocytes: implications for COVID-19
por: Tang, Yan, et al.
Publicado: (2021)

Inhibitors of mTOR in aging and cancer
por: Zhavoronkov, Alexander
Publicado: (2015)

Gerosuppression by pan-mTOR inhibitors
por: Leontieva, Olga V., et al.
Publicado: (2016)

mTOR inhibitors in cancer therapy
por: Xie, Jianling, et al.
Publicado: (2016)

mTor Inhibitors for the Treatment of Endometriosis
por: Barra, Fabio, et al.
Publicado: (2018)

Targeting ganglioneuromas with mTOR inhibitors
por: Tao, Ting, et al.
Publicado: (2021)

Overview of Research into mTOR Inhibitors
por: Mao, Beibei, et al.
Publicado: (2022)

Commentary: Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor
por: Renna, Maurizio
Publicado: (2016)

Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis
por: Qiu, Min, et al.
Publicado: (2022)

Allosteric and ATP-Competitive Inhibitors of mTOR Effectively Suppress Tumor Progression-Associated Epithelial-Mesenchymal Transition in the Kidneys of Tsc2(+/−) Mice
por: Jones, Ashley T., et al.
Publicado: (2019)

IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer
por: De Martino, Maria Cristina, et al.
Publicado: (2019)

Deptor: not only a mTOR inhibitor
por: Catena, Valeria, et al.
Publicado: (2017)

Predicted mechanisms of resistance to mTOR inhibitors
por: Kurmasheva, R T, et al.
Publicado: (2006)

mTOR Inhibitors in Tuberous Sclerosis Complex
por: Curatolo, Paolo, et al.
Publicado: (2012)

Practical considerations for the use of mTOR inhibitors
por: Diekmann, Fritz, et al.
Publicado: (2015)

Role of mTOR Inhibitors in Kidney Disease
por: Kajiwara, Moto, et al.
Publicado: (2016)

mTOR Inhibitors as Radiosensitizers in Neuroendocrine Neoplasms
por: Exner, Samantha, et al.
Publicado: (2021)

Reciprocal effects of mTOR inhibitors on pro-survival proteins dictate therapeutic responses in tuberous sclerosis complex
por: McNamara, Molly C., et al.
Publicado: (2022)

mTOR Signaling Cascade in Psoriatic Disease: Double Kinase mTOR Inhibitor a Novel Therapeutic Target
por: Raychaudhuri, Smriti K, et al.
Publicado: (2014)

Combining mTOR Inhibitors and T Cell-Based Immunotherapies in Cancer Treatment
por: el Hage, Alexandre, et al.
Publicado: (2021)

Myelination and mTOR
por: Figlia, Gianluca, et al.
Publicado: (2017)

Clinical development of mTOR inhibitors in breast cancer
por: Vicier, Cecile, et al.
Publicado: (2014)

Optimising the use of mTOR inhibitors in renal transplantation
por: Russ, Graeme R
Publicado: (2013)

Role of mTOR inhibitor in cholangiocarcinoma cell progression
por: MOOLTHIYA, PENPAK, et al.
Publicado: (2014)

mTOR Inhibitors in Advanced Biliary Tract Cancers
por: Wu, Chao-En, et al.
Publicado: (2019)

Cancer and mTOR inhibitors in kidney transplantation recipients
por: Kao, Chih-Chin, et al.
Publicado: (2018)

Molecular docking of potential inhibitors with the mTOR protein
por: Fathima, JH Shazia, et al.
Publicado: (2021)

Unbiased evaluation of rapamycin's specificity as an mTOR inhibitor
por: Artoni, Filippo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_35soujf1625431erjabjs6c2bd